Apyx Medical (APYX)
(Delayed Data from NSDQ)
$1.36 USD
-0.05 (-3.55%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $1.38 +0.02 (1.47%) 5:24 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for Apyx Medical Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 52 | 45 | 49 | 28 | 28 |
Cost Of Goods | 19 | 15 | 15 | 10 | 9 |
Gross Profit | 34 | 29 | 34 | 18 | 19 |
Selling & Adminstrative & Depr. & Amort Expenses | 51 | 53 | 48 | 38 | 40 |
Income After Depreciation & Amortization | -17 | -24 | -14 | -20 | -21 |
Non-Operating Income | -2 | 1 | 0 | 1 | 1 |
Interest Expense | 2 | 0 | 0 | 0 | 0 |
Pretax Income | -21 | -23 | -15 | -19 | -20 |
Income Taxes | -2 | 0 | 0 | -8 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -19 | -23 | -15 | -12 | -20 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -19 | -23 | -15 | -12 | -20 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -17 | -23 | -14 | -19 | -20 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -17 | -24 | -14 | -20 | -21 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 34.62 | 34.52 | 34.33 | 34.21 | 34.07 |
Diluted EPS Before Non-Recurring Items | -0.53 | -0.67 | -0.44 | -0.57 | -0.58 |
Diluted Net EPS (GAAP) | -0.54 | -0.67 | -0.44 | -0.35 | -0.58 |
Fiscal Year end for Apyx Medical Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | 14.66 | 11.98 | 13.57 | 12.14 | 12.61 |
Cost Of Goods | 5.73 | 4.00 | 4.29 | 4.57 | 4.37 |
Gross Profit | 8.93 | 7.98 | 9.28 | 7.57 | 8.24 |
SG&A, R&D, and Dept/Amort Expenses | 14.71 | 12.62 | 10.52 | 13.18 | 14.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | -5.78 | -4.64 | -1.24 | -5.61 | -5.94 |
Non-Operating Income | 0.44 | 0.23 | 0.83 | 0.05 | 0.02 |
Interest Expense | 1.12 | 0.59 | 0.54 | 0.23 | 0.00 |
Pretax Income | -9.54 | -4.99 | -0.95 | -5.80 | -5.91 |
Income Taxes | 0.09 | -0.32 | 0.07 | -2.27 | 0.15 |
Minority Interest | -0.02 | -0.05 | -0.03 | -0.05 | -0.02 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -9.62 | -4.68 | -1.02 | -3.53 | -6.06 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -9.61 | -4.63 | -0.99 | -3.48 | -6.05 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 34.64 | 34.64 | 34.60 | 34.60 | 34.60 |
Diluted EPS Before Non-Recurring Items | -0.19 | -0.13 | -0.11 | -0.10 | -0.17 |
Diluted Net EPS (GAAP) | -0.28 | -0.13 | -0.03 | -0.10 | -0.17 |